Conjunctivitis in patients with atopic dermatitis treated with dupilumab.

摘要: Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 IL-13 are key cytokines in the immunopathogenesis of AD. New emerging agents include dupilumab, fully human monoclonal antibody directed against IL-4 receptor subunit blocks both signaling has shown significant efficacy patients moderate-to-severe Dupilumab approved for treatment AD, eosinophilic or oral corticosteroid-dependent asthma, chronic rhinosinusitis nasal polyps. Data from phase 2 3 studies have revealed dupilumab generally low rate adverse events, although an increased incidence mild-to-moderate conjunctivitis been reported compared placebo. The present paper reviews data dupilumab-associated risk factors adults AD other atopic diseases clinical trials addresses characteristics options available this clinically highly relevant condition. Additionally, it presents ten real-life setting dupilumab. Dupilumab-associated higher most cases good response to topical treatment, no need suspend therapy.